Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications

Jacqueline L. Gerhart, Amer N. Kalaaji

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking. Objective: We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease. Methods: We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality. Results: Of 334 patients identified, 7 (2.1%) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43%) died within 1 month of diagnosis, and none received PCP prophylaxis. Limitations: Retrospective study design and limited patient group are limitations. Conclusions: PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.

Original languageEnglish (US)
Pages (from-to)957-961
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume62
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Pneumocystis Pneumonia
Connective Tissue Diseases
Immunosuppressive Agents
Immunosuppression
Morbidity
Mortality
Immunocompromised Host
Dermatology
Pneumonia
Retrospective Studies
Therapeutics

Keywords

  • connective tissue disease
  • immunobullous disease
  • immunosuppression
  • Pneumocystis carinii
  • pneumonia

ASJC Scopus subject areas

  • Dermatology

Cite this

Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications. / Gerhart, Jacqueline L.; Kalaaji, Amer N.

In: Journal of the American Academy of Dermatology, Vol. 62, No. 6, 06.2010, p. 957-961.

Research output: Contribution to journalArticle

@article{0247459b73bc4af287467fba25fba5d1,
title = "Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications",
abstract = "Background: Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking. Objective: We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease. Methods: We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality. Results: Of 334 patients identified, 7 (2.1{\%}) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43{\%}) died within 1 month of diagnosis, and none received PCP prophylaxis. Limitations: Retrospective study design and limited patient group are limitations. Conclusions: PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.",
keywords = "connective tissue disease, immunobullous disease, immunosuppression, Pneumocystis carinii, pneumonia",
author = "Gerhart, {Jacqueline L.} and Kalaaji, {Amer N.}",
year = "2010",
month = "6",
doi = "10.1016/j.jaad.2009.07.042",
language = "English (US)",
volume = "62",
pages = "957--961",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications

AU - Gerhart, Jacqueline L.

AU - Kalaaji, Amer N.

PY - 2010/6

Y1 - 2010/6

N2 - Background: Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking. Objective: We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease. Methods: We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality. Results: Of 334 patients identified, 7 (2.1%) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43%) died within 1 month of diagnosis, and none received PCP prophylaxis. Limitations: Retrospective study design and limited patient group are limitations. Conclusions: PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.

AB - Background: Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking. Objective: We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease. Methods: We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality. Results: Of 334 patients identified, 7 (2.1%) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43%) died within 1 month of diagnosis, and none received PCP prophylaxis. Limitations: Retrospective study design and limited patient group are limitations. Conclusions: PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.

KW - connective tissue disease

KW - immunobullous disease

KW - immunosuppression

KW - Pneumocystis carinii

KW - pneumonia

UR - http://www.scopus.com/inward/record.url?scp=77951938014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951938014&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2009.07.042

DO - 10.1016/j.jaad.2009.07.042

M3 - Article

C2 - 19828210

AN - SCOPUS:77951938014

VL - 62

SP - 957

EP - 961

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6

ER -